Navigation Links
Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:8/16/2010

RYE, N.Y., Aug. 16 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference, scheduled for September 12-15 at the New York Palace Hotel in New York City.

Dr. Joan Fallon, Curemark's founder and CEO, will update investors on the progress of the company's clinical research for CM-AT, its autism treatment in development.  She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the FDA for CM – 4612 to treat attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

"We are very happy to have this opportunity to present at the Rodman & Renshaw annual investment conference.  Curemark has achieved a variety of major milestones that we are looking forward to sharing with attendees," Fallon said.  

CM-AT, Curemark's autism treatment, addresses enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  Phase III clinical trials are underway at 13 sites nationwide for CM-AT, which has received Fast Track status from the FDA.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          

Curemark's presentation is part of the 12th annual healthcare conference, an industry track that will be showcased during the Rodman & Renshaw Annual Global Investment Conference
'/>"/>

SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curemark Opens Autism Trials at New Jersey Site
2. Curemark Begins Autism Trials at Two More Sites
3. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
4. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
5. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
9. Curemark Announces Senior Executive Promotions
10. Curemark CEO Presents at Epigenomics Conference
11. Curemark Closes Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
(Date:12/19/2014)... (HealthDay News) -- Injectable drug users who also use ... rate of other substance users, a new study finds. ... the risk of suicide attempt and completed suicide," Didier ... said in a university news release. "However, there are ... know who among substance users were actually more likely ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The cost of cancer ... a new study finds. Researchers examined data from ... diagnosed with colorectal or lung cancer. Of those patients, ... and more than 100 had advanced cancer. Nearly ... pay their medical bills, which was linked with a ...
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... the United States -- along with Angelina Jolie,s chickenpox ... highlighted cracks in the nation,s public health defense against ... released Thursday. Half of U.S. states are poorly ... outbreaks. That was the main conclusion of the report ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Hospital in Franklin, Ind. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... service hospital providing care to the residents of Johnson ...
Breaking Medicine News(10 mins):Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... Phase II Clinical Trial conducted by a cancer institute in ... kidney cancer with the help of bevacizumab and erlotinib[1], the ... and may help in prolonging patient's survival. ,Renal ... especially once it has started to spread to other sites ...
... vision through cell transplants when they treated animals suffering from ... eye damages similar to that seen in many human eye ... which had lost their sight, leading to hopes that it ... happened when immature retinal stem cells were transplanted into the ...
... The AMA Federal Council has rejected outright Pharmaceutical ... are currently being pushed by some medical groups. ... today that any PBS savings derived from changed ... PBS. ,'Evidence-based prescribing information and other ...
... (ADRA) is making preparations for the annual commemoration of World ... is meant to be observed as the international day of ... ,The theme of ADRA's for 2006 is, "AIDS ... and it encourages people all over the world to realize ...
... of developing pancreatic cancer increases by 90% with the intake of ... 70% higher in people who added sugar to any food or ... who added no sugar. ,In spite of high sugar ... the first time that researchers have shown a direct association between ...
... breast cancer charity went bankrupt after it was apparent ... the cause. // Tony Freeman, 40, the man who ... at the High Court in Glasgow for 18 months ... Consultancy (Solutions RMC), raised money for several cancer charities, ...
Cached Medicine News:Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Cell Transplants Can Even Help In Restoring Vision 2Health News:Commemoration of World AIDS Day 2Health News:Charity swindler jailed over cash fraud 2
... analyzer is an affordable system offering ... reliability and consistency of state-of-the-art instrument-based ... way to obtain dependable urine chemistry ... economy of motion and superior efficiency ...
... device consists of a non-compliant balloon with ... longitudinally on its outer surface. When the ... atherotomes score the plaque, creating initiation sites ... as Atherotomy, allows dilatation of the target ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
Medicine Products: